Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre Boissel

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Bulletin De L'Academie Nationale De Medecine|January 30, 2008
[Meta-analysis of clinical trials: uses and pitfalls]Jean-Pierre Boissel
Fundamental & Clinical Pharmacology|March 30, 2007
How to deal with multiple treatment or dose groups in randomized clinical trials? Another approachJean-Pierre Boissel
La Revue Du Praticien|April 17, 2004
[Therapeutic evaluation and the level proof]Jean-Pierre Boissel
Journal of Hypertension|May 16, 2002
Soluble Fas ligand and atherosclerosis in hypertensive patientsJean-Pierre Boissel
Clinical Pharmacokinetics|May 31, 2002
Use of sensitivity functions to characterise and compare the forgiveness of drugsPatrice Nony, Jean-Pierre Boissel
Archives of Cardiovascular Diseases|July 4, 2025
The dawn of in silico clinical trials in cardiovascular diseases: Lessons from the SIRIUS programmeDenis Angoulvant, Jean-Pierre Boissel
Clinical Pharmacokinetics|February 5, 2002
Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor complianceJean-Pierre Boissel, Patrice Nony
Comptes Rendus Biologies|December 1, 2014
An in silico target identification using Boolean network attractors: Avoiding pathological phenotypesArnaud Poret, Jean-Pierre Boissel
Therapie|June 14, 2014
Better defining target populations for drugs with a view to reimbursementJacques Massol, Jean-Pierre Boissel
Therapie|January 22, 2008
[How should one anticipate the assessment of the public health benefit of new medicines?]Jacques Massol, Alain Puech, Jean-Pierre Boissel, et al.
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Bulletin De L'Academie Nationale De Medecine|January 30, 2008
[Meta-analysis of clinical trials: uses and pitfalls]Jean-Pierre Boissel
Fundamental & Clinical Pharmacology|March 30, 2007
How to deal with multiple treatment or dose groups in randomized clinical trials? Another approachJean-Pierre Boissel
La Revue Du Praticien|April 17, 2004
[Therapeutic evaluation and the level proof]Jean-Pierre Boissel
Journal of Hypertension|May 16, 2002
Soluble Fas ligand and atherosclerosis in hypertensive patientsJean-Pierre Boissel
Clinical Pharmacokinetics|May 31, 2002
Use of sensitivity functions to characterise and compare the forgiveness of drugsPatrice Nony, Jean-Pierre Boissel
Archives of Cardiovascular Diseases|July 4, 2025
The dawn of in silico clinical trials in cardiovascular diseases: Lessons from the SIRIUS programmeDenis Angoulvant, Jean-Pierre Boissel
Clinical Pharmacokinetics|February 5, 2002
Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor complianceJean-Pierre Boissel, Patrice Nony
Comptes Rendus Biologies|December 1, 2014
An in silico target identification using Boolean network attractors: Avoiding pathological phenotypesArnaud Poret, Jean-Pierre Boissel
Therapie|June 14, 2014
Better defining target populations for drugs with a view to reimbursementJacques Massol, Jean-Pierre Boissel
Therapie|January 22, 2008
[How should one anticipate the assessment of the public health benefit of new medicines?]Jacques Massol, Alain Puech, Jean-Pierre Boissel, et al.
Pageof 8